- Home
- NXTC vs ZDAI Comparison
NXTC vs ZDAI Comparison
Compare NXTC & ZDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- ZDAI
- Stock Information
- Founded
- NXTC 2015
- ZDAI 2022
- Country
- NXTC United States
- ZDAI Hong Kong
- Employees
- NXTC N/A
- ZDAI N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- ZDAI General Bldg Contractors - Nonresidential Bldgs
- Sector
- NXTC Health Care
- ZDAI Consumer Discretionary
- Exchange
- NXTC Nasdaq
- ZDAI Nasdaq
- Market Cap
- NXTC 13.0M
- ZDAI 13.5M
- IPO Year
- NXTC 2019
- ZDAI 2024
- Fundamental
- Price
- NXTC $5.76
- ZDAI $0.57
- Analyst Decision
- NXTC Strong Buy
- ZDAI
- Analyst Count
- NXTC 2
- ZDAI 0
- Target Price
- NXTC $25.50
- ZDAI N/A
- AVG Volume (30 Days)
- NXTC 16.7K
- ZDAI 6.1M
- Earning Date
- NXTC 11-06-2025
- ZDAI 09-26-2025
- Dividend Yield
- NXTC N/A
- ZDAI N/A
- EPS Growth
- NXTC N/A
- ZDAI N/A
- EPS
- NXTC N/A
- ZDAI N/A
- Revenue
- NXTC N/A
- ZDAI $19,275,673.00
- Revenue This Year
- NXTC N/A
- ZDAI N/A
- Revenue Next Year
- NXTC N/A
- ZDAI N/A
- P/E Ratio
- NXTC N/A
- ZDAI N/A
- Revenue Growth
- NXTC N/A
- ZDAI 43.16
- 52 Week Low
- NXTC $2.69
- ZDAI $0.37
- 52 Week High
- NXTC $19.20
- ZDAI $107.36
- Technical
- Relative Strength Index (RSI)
- NXTC 66.21
- ZDAI 58.22
- Support Level
- NXTC $5.19
- ZDAI $0.39
- Resistance Level
- NXTC $5.15
- ZDAI $0.89
- Average True Range (ATR)
- NXTC 0.27
- ZDAI 0.08
- MACD
- NXTC 0.08
- ZDAI 0.02
- Stochastic Oscillator
- NXTC 89.05
- ZDAI 37.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About ZDAI Primega Group Holdings Limited Ordinary Shares
Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.